Početna › Burkittov limfom › Oregon
Kliničke studije za Burkittov limfom u državi Oregon
8 studija za Burkittov limfom traži sudionike na lokacijama u državi Oregon.
Gradovi u državi Oregon
Službeni tekst studije (engleski)
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- i još 1
U tijeku regrutacijaFaza 3
Od 18 do 39 godina · Oba spola · Ažurirano 2. lis 2026. · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT03739814Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Oregon Health and Science University ( Site 1004), Portland
U tijeku regrutacijaFaza 1/2
6 Months – 25 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT06395103A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
U tijeku regrutacijaFaza 2
Od 1 do 30 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
U tijeku regrutacijaFaza 3
365 Days – 25 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 2
Od 7 do 25 godina · Oba spola · Ažurirano 19. kol 2026. · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579Study of SGR-1505 in Mature B-Cell Neoplasms
- Oregon Health and Science University - Knight Cancer Institute, Portland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT05544019Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.